Skip to main content
OpenTrials
Completed

NCT Number: NCT05727540

The Cohort Study of Uveitis Patients

This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Uveitis Eye Diseases Uveal Diseases

Age range

18 year–90 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion criteria

  • Uveitis during the first month after any intraocular surgery; <18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Treatment and study plan

Primary outcomes

  1. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 12 months post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  2. The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    Time frame: 12 months post-treatment

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

Secondary outcomes

  1. Best corrected visual acuity

    Time frame: 1 month post-treatment

    Best corrected visual acuity

  2. Best corrected visual acuity

    Time frame: 3 months post-treatment

    Best corrected visual acuity

  3. Best corrected visual acuity

    Time frame: 6 months post-treatment

    Best corrected visual acuity

  4. Best corrected visual acuity

    Time frame: 12 months post-treatment

    Best corrected visual acuity

  5. Best corrected visual acuity

    Time frame: 24 months post-treatment

    Best corrected visual acuity

  6. Best corrected visual acuity

    Time frame: 36 months post-treatment

    Best corrected visual acuity

  7. The number of intraocular pressure

    Time frame: 1 month post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  8. The number of intraocular pressure

    Time frame: 3 months post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  9. The number of intraocular pressure

    Time frame: 6 months post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  10. The number of Intraocular pressure

    Time frame: 12 months post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  11. The number of Intraocular pressure

    Time frame: 24 months post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  12. The number of Intraocular pressure

    Time frame: 36 months post-treatment

    The number of Intraocular pressure was examed by non-contact tonometer

  13. Central retinal thickness

    Time frame: 1 month post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  14. Central retinal thickness

    Time frame: 3 months post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  15. Central retinal thickness

    Time frame: 6 months post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  16. Central retinal thickness

    Time frame: 12 months post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  17. Central retinal thickness

    Time frame: 24 months post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  18. Central retinal thickness

    Time frame: 36 months post-treatment

    Central retinal thickness was evaluated by Optical Coherence Tomography

  19. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 1 month post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  20. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 3 months post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  21. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 6 months post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  22. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 24 months post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  23. The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

    Time frame: 36 months post-treatment

    activity of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system

  24. The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    Time frame: 3 months post-treatment

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

  25. The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    Time frame: 6 months post-treatment

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

  26. The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    Time frame: 24 months post-treatment

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

  27. The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions

    Time frame: 36 months post-treatment

    inflammatory chorioretinal and/or inflammatory retinal vascular lesions were evaluated by fundus fluorescein angiography and indocyanine green angiography

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University

Other

Registry information

Official study title

The Cohort Study of Uveitis Patients Based on Real-world Data

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Feb 14, 2023
Registry last updated
Sep 24, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.